Novartis’ ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Where Today's News Shapes Tomorrow
